Turn Therapeutics Inc.

NASDAQ:TTRX

Biotechnology

Healthcare
$8.89 -2.79%

-$0.17 today

Market cap
$271.79M
Beta
2.77
P/E (TTM)
-45.0
EPS (TTM)
-$0.13
52W Low $2.57High $26.50

Volume 0.05M

Average 0.04M

TTRX Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Turn Therapeutics Inc.NASDAQ: TTRX

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow of -$12.23K in Q1 FY2026

Q1 FY2026 investing cash flow was -$12.23K. Trailing-twelve-month investing cash flow was -$165.21K.

Context

  • Investing cash flow grew in size in 2 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly investing cash flow holds near -$12.23K or moves back toward the trailing-twelve-month quarterly average of -$41.3K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$12.23K-61.1% QoQ
Last fiscal yearDec 2025
-$152.99K+53.8% YoY
LTMMar 2026
-$165.21K— YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+53.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(152.99K) USD
Year-over-year change
-53.8%

Investing Cash Flow vs competitors

How TTRX compares with its peers on the latest reported figures

  • TTRX's LTM Mar 2026 investing cash flow of $165.21K is the 6th largest of the 9 companies compared; the peer median is $4.5K.
TTRX Competitors Peer median
Investing Cash Flow for TTRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$99.49M +687.2%——
AGENAgenus Inc.LTM Mar 2026$70.09M +48437.2%—56.6%
SEERSeer, Inc.LTM Mar 2026$55.01M -5.3%—365.8%
ANIXAnixa Biosciences, Inc.LTM Apr 2026$1.47M -83.0%——
HURATuHURA Biosciences, Inc.LTM Mar 2026$233.16K —+232.7%—
TTRXTurn Therapeutics Inc.LTM Mar 2026$165.21K ———
CGTXCognition Therapeutics, Inc.LTM Mar 2026$9K +325.0%——
IRDOpus Genetics, Inc.LTM Mar 2026$0 -100.0%—0.0%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$0 ———
Peer median (excluding TTRX) $4.5K+159.8%+232.7%56.6%

Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(2.29M)(1.77M)(3.19M)
Depreciation & Amortization43.92K47.48K52.75K
Deferred Income Tax000
Stock-Based Compensation640.26K352.83K419.25K
Change in Working Capital229.74K(1.86K)2.37M
Accounts Receivables000
Inventory000
Accounts Payables002.26M
Other Working Capital229.74K(1.86K)105.03K
Other Non-Cash Items6628.65K(2.21M)
Operating Cash Flow(1.38M)(1.36M)(2.56M)
Capital Expenditures(44.31K)(99.48K)(152.99K)
Acquisitions (Net)000
Purchases of Investments000
Sales of Investments000
Other Investing Activities00(152.99K)
Investing Cash Flow(44.31K)(99.48K)(152.99K)
Debt Repayment000
Common Stock Issued500K1.15M6.92M
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities000
Financing Cash Flow500K1.15M6.92M
Effect of Forex Changes000
Net Change in Cash(921.99K)(308.4K)4.2M
Free Cash Flow(1.42M)(1.46M)(2.72M)

Turn Therapeutics Inc.

NASDAQ:TTRX

Intrinsic Alpha fair value

Locked

Current Price

$8.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.